Holen Sie sich die Stockscreener-App
23.59
1.13%
-0.27
Vorhandelsmarkt:
23.98
0.39
+1.65%
Schlusskurs vom Vortag:
$23.86
Offen:
$24.03
24-Stunden-Volumen:
1.68M
Relative Volume:
1.87
Marktkapitalisierung:
$3.99B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-323.01M
KGV:
-10.63
EPS:
-2.22
Netto-Cashflow:
$-272.30M
1W Leistung:
+3.10%
1M Leistung:
-8.78%
6M Leistung:
-15.66%
1J Leistung:
-41.57%
1-Tages-Spanne:
$23.10
$24.42
1-Wochen-Bereich:
$23.10
$25.29
52-Wochen-Spanne:
$22.41
$41.38
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-580-3099
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Vergleichen Sie IMVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
23.59 | 3.99B | 0 | -323.01M | -272.30M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-09 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-13 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | JP Morgan | Overweight |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Immunovant's chief medical officer sells $56,782 in stock - MSN
Immunovant CEO Peter Salzmann sells $208,899 in stock - MSN
Peter Salzmann Sells 8,767 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) CFO Sells $54,761.34 in Stock - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Insider Sells $56,786.89 in Stock - MarketBeat
Immunovant's chief medical officer sells $56,782 in stock By Investing.com - Investing.com Australia
Immunovant CFO Eva Renee Barnett sells $54,756 in stock By Investing.com - Investing.com Canada
Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential - Yahoo Finance
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Bank of America Issues Pessimistic Forecast for Immunovant (NASDAQ:IMVT) Stock Price - Defense World
Bank of America Has Lowered Expectations for Immunovant (NASDAQ:IMVT) Stock Price - MarketBeat
JPMorgan Chase & Co. Lowers Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
JPMorgan Chase & Co. Sells 28,586 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Receives $47.22 Average Price Target from Analysts - MarketBeat
How to Take Advantage of moves in (IMVT) - Stock Traders Daily
Insider Buying: Immunovant, Inc. (NASDAQ:IMVT) Director Buys 16,845,010 Shares of Stock - MarketBeat
Roivant sciences increases stake in Immunovant with $336.9 million purchase By Investing.com - Investing.com Nigeria
Roivant sciences increases stake in Immunovant with $336.9 million purchase - Investing.com
Immunovant to raise $450M from institutional investors - MSN
Immunovant Progresses in Autoimmune Therapy Development - TipRanks
Immunovant (NASDAQ:IMVT) Hits New 12-Month LowWhat's Next? - MarketBeat
Immunovant Raises $450 Million Through Share Purchase Agreement - TipRanks
Immunovant Announces $450 Million Private Placement - The Manila Times
Immunovant Secures Massive $450M Private Placement to Accelerate Drug Development - StockTitan
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $47.22 - MarketBeat
Q1 Earnings Estimate for Immunovant Issued By Zacks Research - Defense World
Immunovant CFO Eva Renee Barnett sells $98,930 in stock - Investing.com India
Immunovant CFO Eva Renee Barnett sells $98,930 in stock By Investing.com - Investing.com Australia
Immunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett Sells 4,105 Shares - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) CEO Peter Salzmann Sells 5,105 Shares - MarketBeat
Warm Autoimmune Hemolytic Anemia (wAIHA) Clinical - openPR
Immunovant stock hits 52-week low at $23.86 amid challenges By Investing.com - Investing.com Nigeria
Myasthenia Gravis Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen R&D, Immunovant - The Globe and Mail
Immunovant (NASDAQ:IMVT) Reaches New 52-Week LowHere's Why - MarketBeat
Immunovant stock hits 52-week low at $23.86 amid challenges - Investing.com India
Myasthenia Gravis Market Poised for Significant Growth from - openPR
(IMVT) Long Term Investment Analysis - Stock Traders Daily
Immunovant (NASDAQ:IMVT) Lowered to “Peer Perform” Rating by Wolfe Research - Defense World
Immunovant (NASDAQ:IMVT) Shares Gap DownHere's What Happened - MarketBeat
Wolfe Research Downgrades Immunovant (NASDAQ:IMVT) to Peer Perform - MarketBeat
Immunovant (NASDAQ:IMVT) Shares Up 4.1%Here's Why - MarketBeat
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth - Yahoo Finance
Immunovant stock hits 52-week low at $24.61 amid market challenges - Investing.com Canada
RSI Alert: Immunovant (IMVT) Now Oversold - Nasdaq
Immunovant stock hits 52-week low at $24.61 amid market challenges By Investing.com - Investing.com South Africa
Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study (NASDAQ:IMVT) - Seeking Alpha
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunovant Inc-Aktie (IMVT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Barnett Eva Renee | Chief Financial Officer |
Jan 15 '25 |
Sale |
23.83 |
2,298 |
54,757 |
324,766 |
| Salzmann Peter | Chief Executive Officer |
Jan 15 '25 |
Sale |
23.83 |
8,767 |
208,900 |
964,225 |
| Roivant Sciences Ltd. | Director |
Jan 13 '25 |
Buy |
20.00 |
16,845,010 |
336,900,200 |
96,650,341 |
| Barnett Eva Renee | Chief Financial Officer |
Jan 08 '25 |
Sale |
24.10 |
4,105 |
98,930 |
327,064 |
| Salzmann Peter | Chief Executive Officer |
Jan 08 '25 |
Sale |
24.10 |
5,105 |
123,030 |
972,992 |
| Pande Atul | Director |
Dec 02 '24 |
Sale |
28.54 |
7,750 |
221,185 |
86,663 |
| Hughes Douglas J. | Director |
Dec 02 '24 |
Sale |
28.54 |
5,425 |
154,830 |
119,585 |
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):